ORION CORPORATION         PRESS RELEASE 18 MAY  2017 at 8:00 a.m. EEST             
         

Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki

Orion Corporation will host Capital Markets Day for institutional investors and analysts today, Thursday, 18 May 2017 in Helsinki. The purpose of the day is to provide an update on the company's business, R&D projects and focus areas  including an  update on the following issues:

• Orion has entered into a collaboration agreement  with a South Korean company Celltrion Healthcare for  exclusive marketing, sales and distribution rights of a biosimilar rituximab (reference product MabThera®) in Scandinavia and Estonia in which Orion already has  exclusive rights for distribution of Celltrion Healthcare's biosimilar product Remsima®  (biosimilar  infliximab, reference product Remicade®). The main indications of MabThera® are non-hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and autoimmune diseases such as rheumatoid arthritis (RA).
   
• Orion has become aware that generic competition of  Dexdor ®  has started due to the launch of generic version of  the product  by a competitor in the German market.  Orion is continuing actions to defend its rights. The effects of the generic competition on sales is difficult  to estimate  at this stage.

Agenda of the CMD:

Presentations and webcast:

All the presentations will be webcasted. As usually, link to the webcast and presentation material will be available at http://www.orion.fi/en/cmd2017 on the day of the event.  A recording of the webcast of the event in English will be published on the Orion website after the event.

                                                                                                                                  
Contact person:
Jari Karlson, CFO, Orion Corporation
tel. +358 50 966 2883 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.